Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
This study is ongoing, but not recruiting participants.
Sponsor:
DePuy International
Information provided by (Responsible Party):
DePuy International
ClinicalTrials.gov Identifier:
NCT00737087
First received: August 15, 2008
Last updated: September 12, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This post-marketing study is designed to collect data relating to the use of the Delta Xtend™ Total Shoulder Replacement System in shoulder with rotator cuff deficiencies. This allows for continued monitoring of the performance and safety of the prosthesis in a broader range of clinical situations.
| Condition | Intervention | Phase |
|---|---|---|
|
Cuff Tear Arthropathy Osteoarthritis With Cuff Deficiency Rheumatoid Arthritis Post Traumatic Injury to Shoulder Revision Surgery of a Failed Anatomic Shoulder Prosthesis |
Device: Delta Xtend Reverse Total Shoulder |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Multi-centred, Non-comparative, Non-randomised, Open, Post Marketing Investigation to Look at the Long-term Clinical Efficacy of the Delta Xtend Reverse Total Shoulder Used in the Treatment of Shoulders With Rotator Cuff Deficiencies. |
Resource links provided by NLM:
Further study details as provided by DePuy International:
Primary Outcome Measures:
- Postoperative functionality through a difference in Constant Score post-treatment, as compared with pre-treatment results. [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Postoperative functionality at 12weeks, 1, 2, 5 and 10years through a difference in the Constant score, ASES score, U-Penn score and EQ-5D as compared with pre-treatment scores. [ Time Frame: 10 years ] [ Designated as safety issue: No ]
- Determine implant survivorship and surgical revision information at 1, 2, 5 and 10years via Kaplan-Meier survival analysis. [ Time Frame: 10 years ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 250 |
| Study Start Date: | October 2007 |
| Estimated Study Completion Date: | August 2021 |
| Estimated Primary Completion Date: | August 2021 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Delta Xtend Reverse Total Shoulder
Orthopaedic implant for total shoulder replacement
|
Device: Delta Xtend Reverse Total Shoulder
Orthopaedic implant for total shoulder replacement
|
Eligibility| Ages Eligible for Study: | 18 Years to 85 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female subjects, aged less than 85 years inclusive.
- Subjects who have cuff tear arthropathy, osteoarthritis with cuff deficiency, rheumatoid arthritis, post traumatic injury, or a need for revision surgery of a failed anatomic prosthesis in the left or right shoulder, which requires (total) shoulder arthroplasty.
- Subjects with radiographic evidence of sufficient bone stock to seat and support the Delta XtendÔ Reverse Total Shoulder System.
- Subjects who in the opinion of the Clinical Investigator are considered suitable for treatment with the Delta Xtend Reverse Total Shoulder System.
- Patients with a life expectancy of greater than 12 months.
- Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.
- Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.
Exclusion Criteria:
- Male and female subjects aged 86 years or older.
- Subjects with complete deltoid muscle palsy in the target joint as determined by clinical evaluation.
- Subjects with active local or systemic infection or with a history of general or local infections in the target joint over the past 12 months.
- Subjects with severe deformities, or tumours, that would impair fixation or proper positioning of the implant.
- Subjects with no significant muscle, nerve or vascular disease.
- Subjects with a pathology that, in the opinion of the Clinical Investigator, will adversely affect healing.
- Known allergic reactions to implant materials (e.g. bone cement, metal, polyethylene) implant corrosion or implant wear debris.
- Subjects with a known history of poor compliance to medical treatment.
- Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.
- Women who are pregnant.
- Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.
- Subjects who have participated in a clinical investigation with an investigational product in the last month.
- Subjects who are currently involved in any injury litigation claims.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00737087
Locations
| Belgium | |
| Universitair Ziekenhuis | |
| Gent, Belgium, B-9000 | |
| France | |
| Clinique Generale D'Annecy | |
| Annecy, France, 74000 | |
| CHRU Reims Hôpital Maison Blanche | |
| Reims, France, 51092 | |
| Polyclinique de l'Atlantique | |
| St Herblain, France, 44819 | |
| Germany | |
| Krankenhaus Munchen Bogenhausen | |
| Munchen, Germany, 81925 | |
Sponsors and Collaborators
DePuy International
Investigators
| Principal Investigator: | Anders Ekelund | St Görans Hospital, Stockholm, Sweden |
More Information
No publications provided
| Responsible Party: | DePuy International |
| ClinicalTrials.gov Identifier: | NCT00737087 History of Changes |
| Other Study ID Numbers: | CT0515 |
| Study First Received: | August 15, 2008 |
| Last Updated: | September 12, 2012 |
| Health Authority: | Belgium: Institutional Review Board Sweden: Institutional Review Board France: Institutional Ethical Committee Germany: Ethics Commission Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by DePuy International:
|
total shoulder replacement rotator cuff osteoarthritis rheumatoid arthritis Delta Extend |
Additional relevant MeSH terms:
|
Arthritis Arthritis, Rheumatoid Joint Diseases Osteoarthritis Wounds and Injuries |
Musculoskeletal Diseases Rheumatic Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013